Evidence map›Paper›PMID 33419162›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer.

Hyo Jeong Lee, Pyeonghwa Jeong, Yeongyu Moon, Jungil Choi, Jeong Doo Heo, Yong-Chul Kim, Sun-Young Han

Open access · goldAbstract read
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.0field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Discovery of a Novel Inhibitor Structure ofMolecules (Basel, Switzerland) · 2022
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Hyo Jeong LeeCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju-si 52828, Korea.
Pyeonghwa JeongBiomedical Science and Engineering and School of Life Sciences, Gwangju Institute of Science & Technology, Gwangju 61005, Korea.
Yeongyu MoonGyeongnam Department of Environmental Toxicology and Chemistry, Korea Institute of Toxicology, Jinju-si 52834, Korea.
Jungil ChoiGyeongnam Department of Environmental Toxicology and Chemistry, Korea Institute of Toxicology, Jinju-si 52834, Korea.
Jeong Doo HeoGyeongnam Department of Environmental Toxicology and Chemistry, Korea Institute of Toxicology, Jinju-si 52834, Korea.
Yong-Chul KimBiomedical Science and Engineering and School of Life Sciences, Gwangju Institute of Science & Technology, Gwangju 61005, Korea.
Sun-Young HanCollege of Pharmacy and Research Institute of Pharmaceutical Sciences, Gyeongsang National University, Jinju-si 52828, Korea.ORCID 0000-0002-7176-4193
Korea Institute of Toxicology · KRGwangju Institute of Science and Technology · KRGyeongsang National University · KR

Funding

National Research Foundation 2018R1A2B6002081
6 · The paper itself

Abstract

Rearranged during transfection (RET), a receptor tyrosine kinase, is activated by glial cell line-derived neurotrophic factor family ligands. Chromosomal rearrangement or point mutations in

Indexed as

kinase inhibitorsLDD-2633RETthyroid cancer

Identifiers

PMID33419162
PMCPMC7825493
OpenAlexW3118352347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.